CD160 Expression in Corneal Vessels

CD160 Ans Corneal Graft: Expression in Corneal Vessels

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05009407

Enrollment

Registered

2021-08-17

Start date

2021-04-21

Completion date

2025-12-22

Last updated

2026-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiogenesis, CD160, Corneal Graft Rejection, Lymphangiogenesis

Keywords

Corneal Graft Rejection, CD160, Angiogenesis, lymphangiogenesis

Brief summary

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Detailed description

After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included. Routine general and eye examination including cornea photographs will be performed. During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.

Interventions

BIOLOGICALImmunohistochemistry and clinical analyses on patients and corneas

Immunohistochemistry and clinical analyses on patients and corneas

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

: * 18-year-old or more patients * enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France * considered able to give an informed written consent

Exclusion criteria

: * none

Design outcomes

Primary

Measure	Time frame	Description
Micro-vascular densities	1 year	neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160

Secondary

Measure	Time frame
Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA	1 year
Evaluation of clinical blood vascular densities on photographs with help of ImageJ software	1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026